NY-AIRCALL
19.7.2022 08:02:06 CEST | Business Wire | Press release
Aircall, the business phone system, today announced that Michael Haske will join the company as Chief Executive Officer (CEO) effective September 2, 2022. Haske, previously the President and Chief Operating Officer at Paylocity, will succeed Aircall CEO Olivier Pailhes. Pailhes co-founded Aircall in 2014 and has led the global company to achieve over $1bn valuation and scale to serve more than 13,000 customers in over 100 countries. Pailhes will remain on the board and continue to serve as a strategic advisor to the company.
Haske joins Aircall at a pivotal time as the company has recently reached centaur status with $100m Annual Recurring Revenue (ARR) and continues to expand globally. He brings nearly three decades of experience in scaling high-growth, cloud-based software businesses and will continue driving Aircall’s global leadership in the cloud communications industry and further its mission to empower every professional to have richer conversations.
“ Michael not only brings the right experience and leadership to accelerate Aircall’s global momentum, he deeply understands the importance of cultivating a diverse, employee-centric culture – which has been instrumental to Aircall’s success to date. I am very proud of the hard work and success the Aircall team has delivered so far, and this change is a testimony of our ambition to build a global leader in the communications space.” — Olivier Pailhes, CEO and Co-Founder, Aircall
Haske most recently served as President and Chief Operating Officer of cloud-based Payroll & Human Resources software company Paylocity, where he led the company’s growth from 100 employees and $15 million in revenue to being on track to reach 5,000 employees and $1 billion in revenue. In 2014 Haske and the Paylocity leadership team took the company public on NASDAQ under ticker symbol PCTY. He’s also served in multiple leadership roles including Executive Sponsor at Blue Marble Payroll, Director of Marketing for Paychex (NASDAQ : PAYX) and various roles with ADP (NYSE : ADP).
“ Olivier and Jonathan set a strong foundation and built an incredible company and culture with tremendous potential and opportunity ahead. It’s an exciting time to be joining Aircall and I look forward to leading its next evolution as we continue to provide the most modern cloud communications tools to our clients and strive to be one the best places to work in the world for our employees. It's an honor to lead the company into its next chapter and beyond.” — Michael Haske, Incoming CEO, Aircall
Pailhes, alongside his co-founders Jonathan Anguelov, Pierre-Baptiste Béchu and Xavier Durand, launched Aircall in 2014 after seeing the need for a better communication platform for businesses to interact with their customers. Jonathan Anguelov will remain in his role as General Manager of Aircall’s EMEA and APAC business. Worldwide, Aircall is among a small group of 150 private SaaS companies to reach Centaur status and will continue building on this recent achievement with expansion plans in Singapore and Madrid later this year.
About Aircall
Aircall is the phone system for modern businesses. An entirely cloud-based voice platform that integrates with popular productivity and help desk tools such as Salesforce, Hubspot, Slack, and many others, Aircall was built to make phone support easy to manage, accessible, transparent, and collaborative. Aircall believes that voice is the most powerful way to communicate with customers, prospects, candidates, and colleagues. It is designed to enable delightful moments of human connection. Aircall was founded in 2014 and has raised over $226 million in funding. With offices in New York, Paris, Sydney, Berlin, London, and Madrid, the company currently has over 700+ employees.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220718005779/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom